via Georgia State University
Treatment of SARS-CoV-2 infection with a new antiviral drug, MK-4482/EIDD-2801 or Molnupiravir, completely suppresses virus transmission within 24 hours, researchers in the Institute for Biomedical Sciences at Georgia State University have discovered.
The group led by Dr. Richard Plemper, Distinguished University Professor at Georgia State, originally discovered that the drug is potent against influenza viruses.
“This is the first demonstration of an orally available drug to rapidly block SARS-CoV-2 transmission,” said Plemper. “MK-4482/EIDD-2801 could be game-changing.”
Interrupting widespread community transmission of SARS-CoV-2 until mass vaccination is available is paramount to managing COVID-19 and mitigating the catastrophic consequences of the pandemic.
Because the drug can be taken by mouth, treatment can be started early for a potentially three-fold benefit: inhibit patients’ progress to severe disease, shorten the infectious phase to ease the emotional and socioeconomic toll of prolonged patient isolation and rapidly silence local outbreaks.
“We noted early on that MK-4482/EIDD-2801 has broad-spectrum activity against respiratory RNA viruses and that treating infected animals by mouth with the drug lowers the amount of shed viral particles by several orders of magnitude, dramatically reducing transmission,” said Plemper. “These properties made MK-4482/EIDD/2801 a powerful candidate for pharmacologic control of COVID-19.”
In the study published in Nature Microbiology, Plemper’s team repurposed MK-4482/EIDD-2801 against SARS-CoV-2 and used a ferret model to test the effect of the drug on halting virus spread.
“We believe ferrets are a relevant transmission model because they readily spread SARS-CoV-2, but mostly do not develop severe disease, which closely resembles SARS-CoV-2 spread in young adults,” said Dr. Robert Cox, a postdoctoral fellow in the Plemper group and a co-lead author of the study.
The researchers infected ferrets with SARS-CoV-2 and initiated treatment with MK-4482/EIDD-2801 when the animals started to shed virus from the nose.
“When we co-housed those infected and then treated source animals with untreated contact ferrets in the same cage, none of the contacts became infected,” said Josef Wolf, a doctoral student in the Plemper lab and co-lead author of the study. By comparison, all contacts of source ferrets that had received placebo became infected.
If these ferret-based data translate to humans, COVID-19 patients treated with the drug could become non-infectious within 24 hours after the beginning of treatment.
The Latest Updates from Bing News & Google News
Go deeper with Bing News on:
- Biopharma Companies With COVID-19 Treatments See $10 Billion Market in 2021on January 19, 2021 at 9:06 am
In the second of three articles, we assess the market for COVID-19 treatments. ( Click here for our outlook for coronavirus vaccines and distribution.) The final article will cover prospects for the ...
- Chemists shorten the synthesis of molnupiravir to prepare for scale-upon January 2, 2021 at 9:31 am
- OK Keytruda: A Pivotal 2021 Awaits For Merck, Signs Point To ~20% Upsideon December 22, 2020 at 2:18 pm
Meanwhile, Merck has collaborated with Ridgeback Bio to develop an orally available antiviral candidate - Molnupiravir - to treat patients with COVID-19. Merck says it has the capacity to produce ...
- FDA Approves Ridgeback Biotherapeutics’ Ebanga for Ebolaon December 22, 2020 at 8:52 am
Ridgeback markets Ebanga TM for the treatment of Ebola and has a late-stage development pipeline which includes molnupiravir for the treatment of COVID-19. Development of molnupiravir is entirely ...
- With FDA nod, Ridgeback's Ebanga joins Regeneron's Inmazeb in the Ebola-fighting arsenalon December 22, 2020 at 8:18 am
In June, Ridgeback ushered its COVID-19 candidate molnupiravir (EIDD-2801) into two separate phase 2 trials in outpatients and hospitalized patients.
Go deeper with Google Headlines on:
Go deeper with Bing News on:
- New tool can calculate COVID-19 transmission risk in poorly-ventilated placeson January 21, 2021 at 2:21 am
Researchers have developed a new online tool that can calculate the risk of COVID-19 transmission in poorly-ventilated places, showing that when two people are in such spaces and neither is wearing a ...
- New online tool can calculate Covid-19 transmission risk in poorly-ventilated placeson January 21, 2021 at 1:41 am
Scientists agree that the vast majority of Covid-19 cases are spread through indoor transmission, whether via aerosols or droplets ...
- Busting myths on airborne transmission of SARS-CoV-2on January 20, 2021 at 7:42 pm
The rapid spread of COVID-19 caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has led to significant research on the mechanisms of how the virus spreads, which is usually by ...
- Covid-19 Vaccines May Cut Transmission as Well as Symptomson January 20, 2021 at 2:50 pm
The Covid-19 vaccination message could be a bit more hopeful. Once again, the Covid-19 health message is getting muddled. Even as officials and scientists urge the public to get vaccinated, they warn ...
- Widespread use of coronavirus face masks can help control virus transmission: studyon January 19, 2021 at 1:30 pm
In the ongoing debate about coronavirus face mask effectiveness, a new study published this week suggests that widespread use of face masks can help to prevent large outbreaks of COVID-19.